The Scientific Platform Cascade: How Strategy Should Flow to the Field

Here's a question every field medical leader should be able to answer but almost none can.

Take any individual MSL on your team. Pick a Tuesday afternoon. Can you trace a direct line from what that MSL is doing right now — the KOL they're meeting, the data they're discussing, the insight they're gathering — back to your company's scientific platform strategy?

Not a general connection. Not "well, they're engaging KOLs about our mechanism, and our scientific platform is about that mechanism." A specific, traceable line: this MSL is in this meeting because of this objective in our plan of action, which was set because of this priority in our medical affairs strategy, which was derived from this element of our scientific platform.

If you can do that, your organization is operating at a strategic maturity level that puts you in a small minority. If you can't — and most leaders can't — there's a structural gap between your field medical strategy and your field execution.

The gap isn't that your team is doing the wrong things. Most MSL teams are doing excellent work. The gap is that nobody built the connecting tissue between what the company is trying to accomplish scientifically and what individual MSLs are doing in the field on any given day. That connecting tissue is what the Scientific Platform Cascade provides.

What a Scientific Platform Is (and Isn't)

Before explaining the cascade, the reader and writer need to share a definition — because "scientific platform" is one of those terms that means different things in different organizations.

A scientific platform is, above all, grounded in the evidence package. It's the company's official medical scientific perspective on what it believes to be true about the disease state — the mechanism of disease, the product's mechanism of action, and the clinical data evidence for safety and efficacy — as well as how this fits into current clinical practice. It includes specific statements the company believes to be true and the individual evidence elements that support each statement. It is referenced. And it clearly identifies when a statement or element is aspirational — when the evidence for that portion is still ongoing or pending. The scientific platform is the foundation of a qualitative field medical program.

That last distinction matters enormously. A scientific platform isn't a marketing narrative dressed in scientific language. It's a living document that separates what the evidence supports from what the evidence generation strategy is designed to prove. It's the intellectual foundation for everything medical affairs does.

A scientific platform is more than a clinical data package. It's the medical scientific perspective that informs how the company's science is understood, communicated, studied, and advanced.

Why it matters for field medical: the scientific platform is supposed to be the "why" behind everything the MSL team does. When an MSL engages a KOL on data, that engagement should connect to a scientific platform priority. When an MSL gathers an insight about how clinicians perceive the drug's medical scientific positioning, that insight should feed back into scientific platform refinement.

In theory, every organization has this connection. In practice, the scientific platform often sits in a slide deck from the last medical strategy offsite, and MSLs are in the field making engagement decisions based on available opportunities, CRM prompts, tools available, and whatever their manager emphasized on the last team call.

The Cascade

The Scientific Platform Cascade is a planning principle: strategy flows down from the scientific platform to field execution, and field intelligence flows back up to refine the strategy. It has seven layers, and the power isn't in any individual layer — most organizations have most of them in some form. The power is in the explicit connections between them.

Layer 1: Scientific Platform Strategy. The company's scientific position. What the evidence supports. What evidence gaps exist. What the medical community needs to understand, and what's aspirational versus established. When this layer is missing or stale, MSLs know their product data but can't articulate why specific data points matter more than others in specific clinical contexts.

Layer 2: Medical Affairs Objectives and Activity Calendar. The translation of scientific platform into organizational goals and the timing and prioritization of the medical affairs activities that inform field medical support and planning. What medical affairs is trying to achieve this year — evidence generation priorities, publication strategy, advisory board outcomes, congress objectives — and when. The conference schedule, advisory board calendar, clinical trial milestones, and publication timelines all shape MSL planning: which KOLs to engage, on what topics, and when. When this layer is missing, the MSL plan of action is written in a vacuum, disconnected from both the broader medical affairs strategy and the operational calendar that drives field support demands.

Layer 3: Field Medical Team Objectives and Key Results. What the field medical function is collectively trying to accomplish, measured in both quantitative and qualitative terms. When this layer is missing, individual MSLs have activity targets but the team doesn't have shared strategic objectives. "Engage 80% of Tier 1 KOLs" is an activity target, not a strategic objective.

Layer 4: Territory Plans and Activity Priorities. The translation of team objectives into territory-specific priorities and individual MSL engagement plans. Which KOLs to prioritize in each territory and why. What scientific platform elements are most relevant to each institution's clinical context. This is the Tuesday afternoon — the specific choices each MSL makes about where to spend their time. When this layer is missing, territory plans are generic copies of the team plan of action with geographic substitutions, and MSLs fill the gaps by making engagement decisions based on convenience, familiarity, or whoever returns their call first. Activity happens, but it's not strategically directed.

Layer 5: Field Execution. What actually happens. The KOL interactions, congress engagements, insight gathering, evidence generation support. This layer is almost never missing — MSLs are in the field doing things. The question is whether what they're doing is connected to what the organization needs them to do.

Layer 6: Strategic Intelligence. The first flow back up. Field insights — what KOLs think, what competitive intelligence shows, what clinical practice is shifting — flowing back through the cascade to inform medical affairs strategy and scientific platform refinement. This is the qualitative signal: what is the field hearing? When this layer is missing, insights are logged in a CRM field (if free text allowed), but may never be synthesized. Or field insights are limited to periodic ad hoc polling of the team. The scientific platform never updates based on what the field is really hearing. The cascade becomes one-directional — strategy pushed down, nothing flowing back up.

Layer 7: Outcome Measurement. The second flow back up — and the one most organizations lack entirely. Did the engagement strategy produce measurable results? Are KOLs adopting the scientific platform? Are the team's priorities advancing the medical affairs objectives set in Layer 2? This layer asks not "what is the field hearing?" but "is the field making a difference?" — and it feeds back to Layers 2 through 4, informing whether priorities, plans, and objectives need to adjust. When this layer is missing, planning operates on assumption rather than evidence. Teams set objectives, execute against them, and then set the next round of objectives without ever closing the loop on whether the previous round produced outcomes. This is the bridge between planning optimization and metrics — between knowing what to do and knowing whether it worked.

The key insight is that the cascade isn't just a top-down planning structure. It's a closed loop — two loops, in fact. Strategic intelligence (Layer 6) feeds back to the scientific platform at the top. Outcome measurement (Layer 7) feeds back to the planning layers in the middle. This is what makes a field medical function strategic rather than just well-organized. A planned organization might have the top-down flow. A strategically mature organization has the feedback loop.

Fragments, Not a Cascade

If you're reading this and thinking "we sort of do this already" — you probably do. Most field medical organizations have fragments of the cascade. A scientific platform deck from the strategy offsite. Activity targets in the CRM. Maybe a POA with objectives that approximate Layers 3 and 4. What they rarely have is the connecting tissue — the explicit linkage between layers that makes every MSL engagement traceable to a strategic objective and every field insight traceable to a strategic decision.

The pattern is consistent: the top layers exist but are vague, the middle layers are generic or MSL-driven, execution happens regardless, and the feedback loops are aspirational at best. Most organizations never close the loop between what they planned and what those plans produced. The cascade framework doesn't ask you to build seven new things. It asks you to connect the things you already have.

What Changes When the Cascade Works

When the connections are made, every MSL can explain how their week connects to the scientific platform — not because they memorized talking points, but because their priorities were derived from it. Insights reach the scientific platform team within weeks, not quarters. The plan of action review becomes a strategic conversation — "did our engagement strategy advance the objectives, and what do we need to adjust?" — rather than an activity audit. New MSLs onboard faster because the cascade gives them strategic context, not just product training.

None of this is utopian. It's operational — and the organizations that achieve it operate at a fundamentally different level of strategic maturity than those running on fragments.

The Maturity Connection

The Scientific Platform Cascade isn't a tool — not yet. It's a planning principle: strategy should flow to the field, and field intelligence should flow back to strategy. How well your organization does this is a direct measure of strategic maturity.

Level 1–2 organizations don't have the cascade. MSLs operate reactively, responding to requests and making engagement decisions without strategic direction. Level 3–4 organizations have the top-down flow but not the feedback loop — strategy reaches the field, but field insights don't reach strategy. Level 5–6 organizations have the full loop operating, with insights systematically flowing back to inform scientific platform refinement. Level 7+ organizations have made the loop so fluid that field medical insights directly influence medical strategy and evidence generation planning.

Where does your organization stand?

[Take the Maturity Assessment →](/assess)

[Read: Planning in the Blue Ocean →](/insights/planning-blue-ocean)

The author is the founder of MSL Blueprint and has spent the last 20 years building, leading, and scaling field medical teams at several biopharmaceutical companies — from team design and territory optimization through scientific platform strategy, KOL engagement frameworks, and qualitative outcome measurement. MSL Blueprint is building the strategic planning and measurement layer that the field medical function has been missing since 1967.

Related reading: - Planning in the Blue Ocean: Why Nobody Has Solved MSL Territory Planning - The Standardization Gap: 1967 to 2026 and Still No Playbook - The 6% Problem: Why Activity Metrics Fail MSL Leaders